The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Insys to Pay $150 Million to Settle U.S. Opioid Kickback Probe

Insys to Pay $150 Million to Settle U.S. Opioid Kickback Probe

August 8, 2018 • By Nate Raymond

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication.

You Might Also Like
  • Former Insys CEO Pleads Guilty to Opioid Kickback Scheme
  • Arizona Accuses Insys of Fraudulent Opioid Marketing Scheme
  • Billionaire Insys Founder Charged in U.S. Opioid Bribe Case

The tentative deal announced by the Arizona-based drugmaker marked a major step in Insys’ efforts to resolve an investigation that has led to several former executives and doctors being criminally charged, including billionaire founder John Kapoor.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The investigation has centered on the company’s efforts to promote Subsys, an under-the-tongue spray intended for managing pain in cancer patients that contains fentanyl, an opioid 100 times stronger than morphine.

The Justice Department has accused Insys of paying kickbacks to doctors to prescribe Subsys, often with fees to participate in sham speaker programs ostensibly meant to educate medical professionals about the drug.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The terms of the agreement in principle require Insys to pay $150 million over five years, with potential additional payments of up to $75 million, the drugmaker said.

“This is a very important step for our company to move forward and continue our transformative efforts to foster a compliant and ethical culture,” Insys Chief Executive Officer Saeed Motahari said in a statement.

The deal came amid a wave of related criminal cases centered on Subsys against medical practitioners and former executives and sales representatives employed by Insys.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

More than a dozen former Insys executives or employees have faced criminal charges, including Kapoor and former CEO Michael Babich, who along with five other former executives or managers were charged in an indictment filed in federal court in Boston.

Prosecutors say Kapoor, Babich and others conspired since 2012 to pay bribes to doctors to prescribe Subsys and sought to defraud insurers into paying for the medication. They have pleaded not guilty to racketeering conspiracy and other charges.

In May, the Justice Department intervened in five whistleblower lawsuits accusing Insys of paying kickbacks and engaging in other illegal practices to promote Subsys.

The department at that time said its action was part of its effort to combat the U.S. opioid epidemic. In 2016, 42,000 people died from opioid overdoses, according to U.S. Centers for Disease Control and Prevention.

 

Filed Under: Pharma Co. News Tagged With: Fentanyl, Insys settlement, Insys Therapeutics Inc, John Kapoor, Michael Babich, Subsys opioid drug, U.S. opioid kickback probe

You Might Also Like:
  • Former Insys CEO Pleads Guilty to Opioid Kickback Scheme
  • Arizona Accuses Insys of Fraudulent Opioid Marketing Scheme
  • Billionaire Insys Founder Charged in U.S. Opioid Bribe Case
  • Rhode Island Doctor Pleads Guilty to Opioid Kickback Scheme

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.